Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cell Therapy Advances but Parkinson's Research Still on Shaky Ground

This article was originally published in Start Up

Executive Summary

A trio of recent papers provides encouragement about the use of cell therapy to treat motor symptoms in Parkinson's disease. But the discussions also highlight how much is not known about the origins of Parkinson's disease, and suggest there may be fundamental limitations to any therapy strategy based on restoring dopamine--be it through implanting dopamine neurons or via existing drugs.

Related Content

Preventing Toxic Effects Of Protein Aggregation In Parkinson’s Disease
Best of the Blog: Start-Up April 2008
Best of the Blog: Start-Up April 2008
Gene Therapy: The Next Big Thing?
Genzyme Licenses Gene Therapy Candidate For Parkinson’s Disease
Cardiac Cell Therapy: Are There Easier Ways to Restore Function? Probably


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts